Cyclerion Therapeutics (CYCN) Equity Ratio (2018 - 2025)

Cyclerion Therapeutics' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.91 for Q4 2025.

• In Q4 2025, Equity Ratio fell 1.56% year-over-year to 0.91; the TTM figure through Dec 2025 stood at 0.91 (down 1.56% YoY), while the FY2025 annual figure was 0.91, down 1.56% from the prior year.
• Equity Ratio was 0.91 for Q4 2025 at Cyclerion Therapeutics, down from 0.92 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.92 in Q4 2024 to a low of 0.34 in Q1 2023.
• Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.85 in 2023.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio plunged 56.96% in 2023, then soared 154.86% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.81 in 2021, then dropped by 28.9% to 0.58 in 2022, then jumped by 45.99% to 0.84 in 2023, then grew by 9.51% to 0.92 in 2024, then decreased by 1.56% to 0.91 in 2025.
• The last three Equity Ratio figures came in at 0.91 (Q4 2025), 0.92 (Q3 2025), and 0.91 (Q2 2025), per Business Quant data.